Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy
Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma
Positive Clinical Data in Anti-PD-1 Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC)
Biologics License Application (BLA) Submission in Post-Anti-PD-1 Advanced Melanoma on Track to Complete in Q1 2023
Strengthened Cash Position to Fund Operating Plan Well into 2024
https://finance.yahoo.com/news/iovance-biotherapeutics-provides-corporate-clinical-130000862.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.